Drug class

Monoclonal Antibody, Interleukin-17A Antagonists

Monoclonal antibody interleukin-17A antagonists are targeted biologic agents designed to neutralize the proinflammatory cytokine interleukin-17A. Read more about Monoclonal Antibody, Interleukin-17A Antagonists

22 drugs in this class 5 manufacturers

Related classes & indications

Antirheumatic Agents (Biologic DMARDS)Biologics, antibodies & cell therapy · 170 prescription drugs Immunomodulator, B-Lymphocyte Stimulator (BLyS)-Spec InhibBiologics, antibodies & cell therapy · 38 prescription drugs Moderate To Severe Plaque PsoriasisTop indication · 173 prescription drugs

Showing 19–22 of 22 drugs

Sort

COSENTYX UNOREADY PEN (secukinumab)

ANTIPSORIATICS · PSORIATIC ARTHRITIS ·+5

Novartis Pharmaceuticals

BIMZELX (bimekizumab-bkzx)

ANTIPSORIATICS · PSORIATIC ARTHRITIS ·+4

UCB, Inc.

BIMZELX AUTOINJECTOR (bimekizumab-bkzx)

ANTIPSORIATICS · PSORIATIC ARTHRITIS ·+4

UCB, Inc.

COSENTYX (secukinumab)

ANTIPSORIATICS · PSORIATIC ARTHRITIS ·+5

Novartis Pharmaceuticals

Filter & compare in the drug finder → Opens the drug finder with Monoclonal Antibody, Interleukin-17A Antagonists preselected. Add indication or manufacturer filters there.

About Monoclonal Antibody, Interleukin-17A Antagonists.

Monoclonal antibody interleukin-17A antagonists are targeted biologic agents designed to neutralize the proinflammatory cytokine interleukin-17A.

By binding directly and selectively to circulating interleukin-17A, these therapeutic antibodies prevent its interaction with the interleukin-17 receptor complex, thereby suppressing downstream inflammatory cascades and chemokine release.

This therapeutic class is primarily indicated for chronic immune-mediated inflammatory disorders, most notably moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other forms of axial spondyloarthritis.